Search Results - Juergens, Rosalyn A, MD

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

    Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study by Hellmann, Matthew D, Dr, Rizvi, Naiyer A, Prof, Goldman, Jonathan W, MD, Gettinger, Scott N, MD, Borghaei, Hossein, DO, Brahmer, Julie R, MD, Ready, Neal E, Prof, Gerber, David E, MD, Chow, Laura Q, MD, Juergens, Rosalyn A, MD, Shepherd, Frances A, Prof, Laurie, Scott A, MD, Geese, William J, PhD, Agrawal, Shruti, PhD, Young, Tina C, MS, Li, Xuemei, MD, Antonia, Scott J, Prof

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

    BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study by Chu, Quincy, Leighl, Natasha B., Surmont, Veerle, van Herpen, Carla, Sibille, Anne, Markman, Ben, Clarke, Stephen, Juergens, Rosalyn A., Rivera, Mirelis Acosta, Andelkovic, Vladimir, Rudin, Charles M., Snow, Stephanie, Kim, Dong-Wan, Sanatani, Michael, Lin, Hongxia, Sanghavi, Kinjal, Tannenbaum-Dvir, Sarah, Basciano, Paul, Lathers, Deanne, Urbanska, Katarzyna, Kollia, Georgia, He, Chunsheng, DiPiero, Andrew, Liu, Yu, Ready, Neal

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: